Clinical trials: Anticholinergics
Pulmonary Disease, Chronic Obstructive
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The safety, tolerability, pharmacokinetics and pharmacodynamics/efficacy profiles of two different doses of GSK233705 will be compared with 2 active comparators and placebo, all medication delivered via dry powder inhaler.
- Trial name
- NCT00422604
- Testing
- salmeterol, tiotropium, GSK233705
- Where
- 11 sites in Finland, Germany and 3 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Urticaria
An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)
This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with chronic urticaria. The primary hypothesis is that the efficacy of desloratadine 10 mg and 5 mg is superior to placebo as…
- Trial name
- NCT01916967
- Testing
- Desloratadine
- Volunteers
- 239 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
SPIRIVA in Ususal Care
The objective of the study is to determine the effect on lung function when either SPIRIVA once daily or placebo once daily is added to the usual therapy (care) of COPD patients naïve to anticholinergic agents managed in primary…
- Trial name
- NCT00274079
- Testing
- SPIRIVA
- Where
- 44 sites in United Kingdom
- Volunteers
- 395 people
- Sponsor
- Boehringer Ingelheim
Hyperhidrosis
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects.
- Trial name
- NCT02193139
- Testing
- WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Watson Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva
To evaluate acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of tiotropium (Spiriva)
- Trial name
- NCT00274066
- Testing
- Tiotropium + ipratropium, Tiotropium + fenoterol
- Where
- 5 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of GSK704838 In Healthy Volunteers
GSK704838C is a potent, pan-active mAChR antagonist, which is being developed for once-daily treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00539825
- Testing
- GSK704838
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Palmar Hyperhidrosis
Severe Primary Hand Hyperhidrosis Treatment With Topical Administration of Victorhy
The objective of this study is to assess the efficacy and safety of Victorhy, a topical TTB gel in patients with severe primary hand hyperhidrosis.
- Trial name
- NCT06645509
- Testing
- TTB gel (dose 1), TTB gel (dose 2)
- Where
- 4 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Dryox Health
Pulmonary Disease, Chronic Obstructive
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
- Trial name
- NCT00950807
- Testing
- Tiotropium, GSK573179
- Where
- 19 sites in United States, Germany
- Volunteers
- 176 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
Primary objective The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory…
- Trial name
- ELITRA (NCT02296411)
- Testing
- CHF 5259 12.5 µg + Qvar
- Where
- 28 sites in Bulgaria, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate COPD-related clinical outcomes and total healthcare utilization in commercially insured (at least 40 years with a subanalysis of those aged 65 years and older) COPD population associated with the use of…
- Trial name
- NCT01331694
- Testing
- fluticasone/salmeterol combination (FSC) 250/50mcg, tiotropium, ipratropium bromide alone or in fixed dose combination with albuterol
- Volunteers
- 76,130 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
QTc Study GSK573719+GW642444
This is a randomized, placebo controlled, four period incomplete block,crossover thorough QT study to estimate the effect of repeat dose GSK573719/GW642444M (Vilanterol) combination and GSK573719 monotherapy on the QTc interval…
- Trial name
- NCT01521377
- Testing
- Moxifloxacin, GSK573719/Vilanterol 125/25mcg, GSK573719
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bladder Dysfunction, Multiple Sclerosis
Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction
The aims of this prospective, randomized study are: To assess the effect of clean intermittent catheterization (CIC) To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when…
- Trial name
- NCT00913510
- Testing
- CIC using LoFric Primo, Anticholinergic medication
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Wellspect HealthCare
Pulmonary Disease, Chronic Obstructive
Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation
This retrospective database study will assess differences in the risk of re-hospitalization and other COPD-related exacerbations and costs for patients receiving fluticasone propionate/salmeterol xinafoate combination 250/50…
- Trial name
- NCT01381458
- Testing
- FSC, ACs
- Volunteers
- 1,936 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers
Study will investigate the pharmacodynamics of a dual pharmacophore in which a combination of GSK961081 and Propanolol is used to give a total effect of bronchodilation.
- Trial name
- NCT00687700
- Testing
- GSK961081, Propranolol
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Motion Sickness
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With…
- Trial name
- NCT03988530
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the…
- Trial name
- NCT02371629
- Testing
- NVA237, Salbutamol
- Where
- 81 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 776 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work…
- Trial name
- NCT00783003
- Testing
- GSK233705 and GW642444, GW642444, GSK233705
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products
The purpose of this study is to compare the absorption of two different inhalation products with the reference product in healthy volunteers.
- Trial name
- NCT02676297
- Testing
- tiotropium
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Solventum US LLC
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113361 (NCT01313637)
- Testing
- GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg
- Where
- 157 sites in United States, Belgium and 12 more
- Volunteers
- 1,493 people
- Sponsor
- GlaxoSmithKline